Recent guidelines have recommended considering the use of a mineralocorticoid receptor antagonist (MRA) and the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with heart failure and mildly reduced ejection fraction (HFmrEF).1, 2. Here, NR3C2 is linked to heart failure.